Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) is described in its own communications as a leader in life science research and clinical diagnostics products. Based in Hercules, California, the company operates globally and regularly issues news on its financial performance, technology platforms, and corporate developments. This news page aggregates recent BIO stock headlines and company announcements.
Investors and analysts following Bio-Rad can find updates on quarterly financial results, including segment performance for the Life Science and Clinical Diagnostics groups and commentary on factors such as academic research funding, biotech funding conditions, and reimbursement trends in key markets. The company frequently discusses both GAAP and non-GAAP results, along with explanations of how non-GAAP measures are used in its internal analysis.
Bio-Rad’s news flow also covers product and technology updates, particularly around its Droplet Digital PCR (ddPCR) portfolio. Recent releases describe the launch of new ddPCR platforms, the integration of technologies from the acquisition of Stilla Technologies, and webinars or presentations focused on its ddPCR product line. These items provide insight into how the company is expanding its presence in genomics research and applied science applications.
Additional news items include announcements about participation in healthcare and investor conferences, leadership appointments, and historical and corporate milestones. For example, the company has reported on executive leadership changes and has issued statements regarding the passing of its co-founder and Director Emeritus, Alice N. Schwartz. Users interested in BIO news can use this page to review these updates in one place and to track how Bio-Rad communicates its strategy and operations over time.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q4 and full year 2021 on February 10, 2022, after market close. The company will host a conference call at 3 PM PT (6 PM ET) to discuss the results. Investors can listen by calling in or via a live webcast. Bio-Rad is a leader in life science research and clinical diagnostics, with 2020 revenues exceeding $2.5 billion.
Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, will participate in a virtual Fireside Chat at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. Key executives, including President and CEO Norman Schwartz, will present insights during the event. The live webcast can be accessed via the Bio-Rad Investor Relations website. Founded in 1952 and based in Hercules, California, Bio-Rad reported revenues exceeding $2.5 billion in 2020, serving a diverse clientele in various markets.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) has appointed Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He takes over from Annette Tumolo, who will retire at that time. Dr. May previously led the Digital Biology Group, overseeing significant growth and acquisitions. His extensive experience in commercial operations makes him well-suited for this role. Bio-Rad, based in Hercules, California, achieved revenues exceeding $2.5 billion in 2020.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
Bio-Rad Laboratories reported third-quarter 2021 net sales of $747.0 million, a 15.4% increase from $647.3 million year-over-year. The gross margin improved to 58.6% from 56.7% in Q3 2020. The Life Science segment sales rose 15.3% to $373.5 million, while Clinical Diagnostics saw a 15.5% increase to $372.2 million. Net income surged to $3,928.0 million or $129.96 per diluted share, compared to $1,314.8 million or $43.64 in the prior year. The company updated its 2021 guidance, now expecting 12-13% currency-neutral revenue growth.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q3 2021 on October 28, 2021, after market close. A conference call will follow at 2 PM PT to discuss the results. Interested parties can listen by calling 844-200-6205 in the U.S. or 929-526-1599 internationally, using access code: 535686. The results and further details can be accessed on the company’s website. Bio-Rad, established in 1952, exceeded $2.5 billion in revenue in 2020 and operates worldwide with approximately 7,800 employees.
Bio-Rad Laboratories (NYSE: BIO) announced participation in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on September 9 at 11:40 AM (Pacific Time). Interested parties can access the live webcast via the Investor Relations section of bio-rad.com. Bio-Rad, a leader in life science research and clinical diagnostics, reported over $2.5 billion in revenue in 2020 and has been operational since 1952. Headquartered in
Bio-Rad Laboratories reported strong Q2 2021 financial results, with net sales of $715.9 million, up 33.4% from Q2 2020. The Life Science segment sales rose 32.6% to $334.2 million, while Clinical Diagnostics grew 34.3% to $380.2 million. Gross margin improved to 56.1% from 54.6% a year earlier. Net income was $914.1 million, or $30.32 per share, impacted by equity security valuations. The company updated its 2021 outlook, forecasting 10.0% to 10.5% non-GAAP currency-neutral revenue growth.
Bio-Rad Laboratories (NYSE: BIO and BIOb) announced a final settlement with 10x Genomics (Nasdaq: TXG) to resolve multiple litigations across various regions, including Massachusetts and Germany. This settlement includes a global patent cross-license, granting Bio-Rad broad freedom-to-operate in the single-cell genomics market, along with past and future royalties. Both companies maintain their patent rights, affirming their validity. The CEO of Bio-Rad expressed satisfaction over the resolution, highlighting the value of the company's intellectual property rights.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will announce its Q2 2021 financial results on July 29, 2021, after market close. The results will be discussed in a conference call at 3 PM PT (6 PM ET). Investors can listen in by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, with a passcode of 5382265. A webcast will also be available on the company’s website under “Quarterly Results” and will remain accessible for one year. Bio-Rad, based in Hercules, California, reported revenues of over $2.5 billion in 2020.